title: The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia.
abstract: BACKGROUND
  A large proportion of patients with acute myeloid leukemia (AML) are not fit for intensive and potentially curative therapy due to advanced age or comorbidity. Previous studies have demonstrated that a subset of these patients can benefit from disease-stabilizing therapy based on all-trans retinoic acid (ATRA) and valproic acid. Even though complete hematological remission is only achieved for exceptional patients, a relatively large subset of patients respond to this treatment with stabilization of normal peripheral blood cell counts.
  
  
  METHODS
  In this clinical study we investigated the efficiency and safety of combining (i) continuous administration of valproic acid with (ii) intermittent oral ATRA treatment (21.5 mg/m2 twice daily) for 14 days and low-dose cytarabine (10 mg/m2 daily) for 10 days administered subcutaneously. If cytarabine could not control hyperleukocytosis it was replaced by hydroxyurea or 6-mercaptopurin to keep the peripheral blood blast count below 50 × 109/L.
  
  
  RESULTS
  The study included 36 AML patients (median age 77 years, range 48 to 90 years) unfit for conventional intensive chemotherapy; 11 patients responded to the treatment according to the myelodysplastic syndrome (MDS) response criteria and two of these responders achieved complete hematological remission. The most common response to treatment was increased and stabilized platelet counts. The responder patients had a median survival of 171 days (range 102 to > 574 days) and they could spend most of this time outside hospital, whereas the nonresponders had a median survival of 33 days (range 8 to 149 days). The valproic acid serum levels did not differ between responder and nonresponder patients and the treatment was associated with a decrease in the level of circulating regulatory T cells.
  
  
  CONCLUSIONS
  Treatment with continuous valproic acid and intermittent ATRA plus low-dose cytarabine has a low frequency of side effects and complete hematological remission is seen for a small minority of patients. However, disease stabilization is seen for a subset of AML patients unfit for conventional intensive chemotherapy.
authors.affiliation: Section for Hematology, Institute of Medicine, University of Bergen, Bergen, Norway. hanne.fredly@med.uib.no.
authors.forename: Hanne
authors.initials: H
authors.lastname: Fredly
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Ersvær
authors.forename: Astrid Olsnes
authors.initials: AO
authors.lastname: Kittang
authors.forename: Galina
authors.initials: G
authors.lastname: Tsykunova
authors.forename: Bjørn Tore
authors.initials: BT
authors.lastname: Gjertsen
authors.forename: Oystein
authors.initials: O
authors.lastname: Bruserud
references.citation: Cancer Res. 2006 Sep 1;66(17):8903-11
references.pmid: 16951208
references.citation: Br J Haematol. 2010 Jul;150(1):72-82
references.pmid: 20456355
references.citation: Cancer. 2005 Dec 15;104(12):2717-25
references.pmid: 16294345
references.citation: Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7473-8
references.pmid: 20368434
references.citation: Blood. 2006 May 1;107(9):3481-5
references.pmid: 16455952
references.citation: Onkologie. 2008 Nov;31(11):629-33
references.pmid: 19145098
references.citation: J Clin Oncol. 2003 Dec 15;21(24):4642-9
references.pmid: 14673054
references.citation: Br J Haematol. 2011 Mar;152(5):524-42
references.pmid: 21314823
references.citation: Blood. 2000 Dec 1;96(12):3671-4
references.pmid: 11090046
references.citation: Am J Clin Oncol. 1982 Dec;5(6):649-55
references.pmid: 7165009
references.citation: Leuk Res. 2009 Jun;33(6):779-87
references.pmid: 19007987
references.citation: Blood. 2008 Feb 1;111(3):1060-6
references.pmid: 17962510
references.citation: Oncotarget. 2010 May;1(1):34-42
references.pmid: 21293051
references.citation: Blood. 2010 Jan 21;115(3):453-74
references.pmid: 19880497
references.citation: Crit Rev Oncol Hematol. 2007 Oct;64(1):19-30
references.pmid: 17765568
references.citation: Blood. 2008 Sep 1;112(5):1638-45
references.pmid: 18565853
references.citation: J Clin Oncol. 2012 Jul 10;30(20):2492-9
references.pmid: 22585697
references.citation: Haematologica. 2005 Jul;90(7):986-8
references.pmid: 15996941
references.citation: Int J Cancer. 2011 Sep 15;129(6):1373-81
references.pmid: 21105040
references.citation: Clin Cancer Res. 2009 May 15;15(10):3325-32
references.pmid: 19417016
references.citation: Am J Hematol. 2012 Apr;87(4):368-76
references.pmid: 22374841
references.citation: BMC Immunol. 2010 Jul 09;11:38
references.pmid: 20618967
references.citation: J Clin Oncol. 2010 Feb 1;28(4):562-9
references.pmid: 20026804
references.citation: Eur J Haematol. 2005 Oct;75(4):293-8
references.pmid: 16146535
references.citation: Haematologica. 2006 Nov;91(11):1513-22
references.pmid: 17082009
references.citation: Haematologica. 2009 Oct;94(10):1375-82
references.pmid: 19794082
references.citation: Blood. 1999 Aug 15;94(4):1192-200
references.pmid: 10438706
references.citation: Blood. 2005 Oct 15;106(8):2912-9
references.pmid: 15994282
references.citation: Ann Oncol. 2006 Feb;17(2):281-5
references.pmid: 16373393
references.citation: Blood. 2010 Mar 4;115(9):1690-6
references.pmid: 20018913
references.citation: Blood. 2010 Nov 25;116(22):4422-9
references.pmid: 20668231
references.citation: J Clin Oncol. 2010 Feb 1;28(4):556-61
references.pmid: 20026803
references.citation: Expert Opin Ther Targets. 2006 Feb;10(1):51-68
references.pmid: 16441228
references.citation: Clin Exp Immunol. 2009 Nov;158(2):199-204
references.pmid: 19737137
references.citation: Int J Lab Hematol. 2008 Dec;30(6):519-25
references.pmid: 18983304
references.citation: Am J Hematol. 2012 Jan;87(1):89-99
references.pmid: 22180162
references.citation: Cancer Treat Rev. 2004 Feb;30(1):103-17
references.pmid: 14766128
references.citation: Crit Rev Oncol Hematol. 2009 Feb;69(2):168-74
references.pmid: 18778950
references.citation: Blood. 2007 Oct 1;110(7):2302-8
references.pmid: 17596541
references.citation: Br J Haematol. 2007 Feb;136(4):624-7
references.pmid: 17223919
references.citation: Curr Pharm Biotechnol. 2007 Dec;8(6):388-400
references.pmid: 18289048
references.citation: Cancer. 2005 Jul 1;104(1):101-9
references.pmid: 15895376
references.citation: Platelets. 2006 Aug;17(5):296-302
references.pmid: 16928601
references.citation: Cancer. 2006 Nov 1;107(9):2099-107
references.pmid: 17019734
references.citation: Blood. 2006 Jul 15;108(2):419-25
references.pmid: 16609072
references.citation: Expert Opin Investig Drugs. 2008 Nov;17(11):1623-33
references.pmid: 18922099
references.citation: Clin Epigenetics. 2013 Jul 30;5(1):12
references.pmid: 23898968
references.citation: J Clin Oncol. 2012 Jul 20;30(21):2670-7
references.pmid: 22689805
references.citation: Leuk Res. 2011 Aug;35(8):991-7
references.pmid: 21474179
references.citation: Semin Immunol. 2007 Oct;19(5):318-30
references.pmid: 18023361
references.citation: Expert Opin Investig Drugs. 2011 Feb;20(2):287-95
references.pmid: 21192773
references.citation: Leukemia. 2011 Feb;25(2):226-35
references.pmid: 21116282
references.citation: Ann Hematol. 2005 Dec;84 Suppl 1:61-6
references.pmid: 16270213
references.citation: J Clin Oncol. 2011 Nov 20;29(33):4417-23
references.pmid: 21969499
references.citation: J Clin Oncol. 2013 May 10;31(14):1795-6
references.pmid: 23547076
references.citation: Cancer. 2007 Mar 15;109(6):1114-24
references.pmid: 17315155
references.citation: Ann Hematol. 1999 Jun;78(6):271-3
references.pmid: 10422629
references.citation: Arch Intern Med. 2002 Jul 22;162(14):1597-603
references.pmid: 12123403
references.citation: Cancer. 2012 Sep 15;118(18):4471-7
references.pmid: 22282348
references.citation: Cancer. 2006 Jan 1;106(1):112-9
references.pmid: 16323176
references.citation: Leuk Lymphoma. 2012 Jun;53(6):1077-83
references.pmid: 22098405